Status: Recruiting
Two Dose Levels of Privigen in Pediatric CIDP
A randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible CIDP, either previously exposed to IVIG treatment or unexposed to IVIG treatment
Participants needed: 30
Trial details
Phase: Phase 4Age: 2-17Biological sex: AllType: InterventionalSponsor: CSL BehringUpdated: Jun 1, 2026Locations: 9
Eligibility criteria
- Male or female subjects 2 to ≤ 17 years of age with confirmed or possible CIDP...
- Absence of CIDP symptoms [+7]